Bioxodes plans to raise EUR 70m in a Series B round to finance the completion of clinical trial andbring to market its hemorrhagic stroke drug candidate, CEO Marc Dechamps said. The Belgian biotechnology company started talks with investors in April, following the receipt ofpositive interim data from the Phase 2a study, he said. It plans to complete the funding round by late2026 or 2027, targeting global VCs as investors, he added. Management has mandated KBC Securities to assist with the funding round, Dechamps said.